Splenopentin

Splenopentin (SP-5; sequence Arg-Lys-Glu-Val-Tyr) is a synthetic pentapeptide corresponding to residues 32-36 of splenin, a 49-amino acid polypeptide hormone first isolated from mammalian spleen tissue and characterized by Audhya, Scheid, and Goldstein in 1984. Splenin was initially detected as a crossreacting species during radioimmunoassay of thymopoietin and is expressed principally in spleen and lymph nodes.

The critical structural distinction between splenopentin and its thymic analog thymopentin (TP-5; Arg-Lys-Asp-Val-Tyr) is a single amino acid substitution at position 34: glutamic acid in splenin versus aspartic acid in thymopoietin. This single change confers contrasting receptor specificities and divergent biological activities. Thymopentin induces T-cell precursor differentiation while inhibiting B-cell maturation and affecting neuromuscular transmission. Splenopentin, by contrast, induces differentiation of both T-cell and B-cell precursors and exerts no neuromuscular activity.

At the cellular level, SP-5 and its analogs stimulate active T-cell rosette (CD2R) formation and enhance interleukin-2 (IL-2) secretion from lymphocytes. The rise in IL-2 is proposed to account, at least in part, for augmentation of natural killer (NK) cell cytotoxic activity observed with SP-5 analogs in vitro. In hematopoietic assays, SP-5 acts as a co-stimulant for granulocyte-macrophage colony-stimulating factor (GM-CSF), increasing granulocyte-macrophage and macrophage colony-forming unit output from bone marrow progenitor cells.

The published evidence base for splenopentin is modest and concentrated in the late 1980s and early 1990s, originating primarily from East German research groups at the Charite (Berlin) and Friedrich Schiller University (Jena). No large randomized controlled trials, systematic reviews, or approved regulatory submissions have been published.

The foundational characterization was established by Audhya, Scheid, and Goldstein (PNAS, 1984; PMID 6585832), demonstrating that synthetic SP-5 reproduces the full immunological activity of intact splenin in murine assays, including selective promotion of both T- and B-cell differentiation without neuromuscular effects.

Weber and colleagues (Int J Immunopharmacol, 1990; PMID 2292457) administered diacetyl-SP-5 at 0.5 mg/kg subcutaneously in three doses at 24-hour intervals to sublethally irradiated mice. Treated animals showed accelerated recovery of peripheral leukocyte counts and spleen cellularity, increased granulocyte-macrophage colony-forming units in bone marrow, and improved splenic plaque-forming responses to a T-cell-dependent antigen versus irradiated controls. The authors identified the compound as a candidate for managing secondary bone marrow depression.

Diezel and colleagues (Int J Immunopharmacol, 1993; PMID 8505137) demonstrated in vitro that DA SP-5 co-stimulates GM-CSF-induced colony formation from human bone marrow cells and that pre-incubation with DA SP-5 partially preserved colony-forming capacity against AZT-induced myelosuppression.

The most directly human-relevant data involves BCH 069, the diacetylated derivative. Simon et al. (Allergol Immunopathol, 1990; PMID 2251976) conducted a controlled trial in hay fever patients during pollen season. Intravenous 50 mg three times weekly for six weeks produced a significantly attenuated rise in grass-pollen-specific IgE and IgG4 and reduced clinical symptoms versus placebo; subcutaneous delivery at the same frequency and dose was reported as ineffective. Eckert et al. (Exp Clin Endocrinol, 1990; PMID 2083570) found that splenopentin consistently improved engraftment in murine allogeneic bone marrow transplantation across non-H-2 strain combinations, but its effects on graft-versus-host reaction ranged from complete suppression to fatal enhancement, a finding that precluded direct clinical translation.

Typical dosage: 1-5 mg (as needed).

No approved therapeutic dosage regimen exists for splenopentin or its diacetylated derivative BCH 069 in any major regulatory jurisdiction. The following protocols are derived entirely from published research studies.

In the primary murine radiation recovery study (Weber et al., 1990), diacetyl-SP-5 was administered subcutaneously at 0.5 mg/kg in three doses given at 24-hour intervals.

The only published human dosing data involves BCH 069 (diacetyl-splenopentin):

• Intravenous: 50 mg, three times weekly for six weeks — this route produced measurable immunological effects in the hay fever controlled trial • Subcutaneous: 50 mg, three times weekly for four weeks — this route was reported as ineffective in the hay fever trial, though no adverse effects were attributed to it • Hormonal monitoring in the same population confirmed no significant changes in pituitary, adrenal, gonadal, or thyroid hormone levels at these doses and schedules

Route of administration mattered considerably in the one published controlled human study; intravenous delivery was required for a measurable immunological response. No established oral dosing protocol exists in the peer-reviewed literature, though patent filings describe oral and inhalation formulations as theoretical delivery options without clinical dosing data.

This information is presented for educational and scientific reference only and does not constitute medical advice. Splenopentin and its derivatives are not approved therapeutic agents in any jurisdiction reviewed. Self-administration is unsupported by clinical evidence and carries undefined risk.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most formally documented combination strategy is co-administration of splenopentin (Arg-Lys-Glu-Val-Tyr) with thymopentin (Arg-Lys-Asp-Val-Tyr), as described in a 2010 patent application. The proposed biological rationale is complementarity: thymopentin preferentially drives T-cell differentiation while splenopentin additionally promotes B-cell maturation, and together they may address a broader spectrum of immune reconstitution. The patent describes a formulation of approximately 30% splenopentin to 70% thymopentin by weight for autoimmune, inflammatory, neoplastic, and infectious indications. No published clinical trial data for this specific combination has been identified.

In the compounding and research-peptide community, splenopentin is occasionally mentioned alongside other immune-modulating peptides such as thymalin, thymogen (Glu-Trp), or thymosin alpha-1, on the premise that covering both splenic and thymic immune axes may produce broader immune support. This rationale is biologically plausible given the distinct and complementary receptor targets of splenic versus thymic peptides, but is entirely anecdotal; no controlled human data supports these combinations.

Splenopentin is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Well-tolerated

Formal safety data for splenopentin is limited to the small human studies conducted with BCH 069 (diacetyl-splenopentin) in the early 1990s. At 50 mg intravenous or subcutaneous three times weekly, no inflammatory biochemical signs were detected and no increase in bronchomotoric reactivity was observed versus placebo (Simon et al., Allergol Immunopathol, 1990; PMID 2251976). A dedicated endocrine safety study (Simon et al., Exp Clin Endocrinol, 1990; PMID 2083571) confirmed no significant effects on prolactin, LH, TSH, cortisol, testosterone, progesterone, estradiol, or thyroxine, consistent with splenopentin's lack of neuromuscular activity compared with thymopentin.

A significant safety concern identified in animal work is splenopentin's unpredictable effect on graft-versus-host reaction. In one of three non-H-2 murine strain combinations studied by Eckert et al. (1990; PMID 2083570), splenopentin dramatically enhanced GVHR severity with substantial mortality. The authors explicitly cautioned against transplantation applications in humans until predictive parameters are established. This finding suggests particular caution in any clinical context involving allogeneic immune cell transfer or in patients with conditions susceptible to exaggerated immune reactions.

No large clinical safety database, formal pharmacovigilance program, drug interaction studies, or long-term human toxicology data exist. Contraindications have not been formally established. Splenopentin is not an approved drug in any jurisdiction. Its immunostimulatory profile implies potential concern in autoimmune diseases, active allograft recipients, and patients on immunosuppressive regimens, though these risks have not been formally studied in humans.